neutralizing antibody for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. anti-inflammatoty and immuno-therapy
vs. Immunostimulants drugs
vs. neutralizing antibody
vs. casirivimab/imdevimab (Ronapreve)
vs. control
vs. placebo
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

phase 2, 0 NCT04787211

amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) vs. placebo

COVID-19 mild to moderate

CORIMMUNO-BEVA, 0 NCT04344782

bevacizumab vs. standard of care

COVID-19 mild to moderate

Suzuki, 2021

casirivimab/imdevimab (Ronapreve) vs. control

COVID-19 mild to moderate

Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 NCT04426695

casirivimab/imdevimab (Ronapreve) vs. placebo

COVID-19 mild to moderate

POLYCOR phase IIb (Gaborit), 2021 NCT04453384

XAV-19 vs. placebo

COVID-19 mild to moderate

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open